RE:Germanyarcheo753 wrote: Looks like 2 years before any revenue from German operations. From page 7.
In 2020, Ceapro bought equipment from a larger scale supercritical plant in Germany and engaged a manufacturer for the modification and conversion of the retained equipment to comply with PGX unique requirements. The new PGX installation will be designed for an initial capacity of 20 metric tons per year mostly for the production of yeast beta glucan to be sold as a nutraceutical (immunomodulating) product.The design and manufacturing of modular PGX equipment should take between six to nine months while the instal-lation of the PGX plant, utilities, facilities upgrades and commissioning of the production facility should take an ad-ditional nine to twelve months. The final decision on location is pending upon receipt of invitational packages from different cities. While this project is taking shape in Europe, considerable amount of work has been completed for the installation of a commercial scale impregnation unit at the Edmonton based facility for the production of new chemical complexes. It is anticipated that commissioning of this impregnation system will be completed during the second half of 2021. Commercial scale up level is critical for out-licensing applications produced using the PGX Technology.
It would seem that a NCC deal should be struck in H1 2021 and we'd be ready for production in H2/Q1 2022. That would be a nice bump in sales and earnings as well as cash holdings.
I wonder the capacity and how many deals/ products they could make out of Edmonton.
Then that should lead into the German plant in ~2 years with further bump in sales and output.
Tack on the Cholesterol pill and this could be a very different company in 2023